Lawrence Ginsberg, MD
Red Oak Psychiatry Associates, P. A.
Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit hyperactivity disorder (ADHD) and bipolar disorder in both children and adults, as well as generalized anxiety disorder and panic disorders. Dr. Ginsberg consults for over 20 pharmaceutical companies and has been an investigator on numerous drug trials for anxiety, bipolar disorder, and ADHD. (This is me - Update Profile)
| 1991 - present | President Red Oak Psychiatry Associates, P. A. |
|---|---|
| 1985 - 1990 | Physician Post Oak Psychiatry Assoc. |
GLG Study Groups with Lawrence Ginsberg, MD(?)
| Study Group Name | Members |
|---|---|
| Addiction Medicine Psychiatrists (US) | 99 |
| Lexapro Prescribers: Psychiatrists (US) | 63 |
| SSRI Prescribers (US) | 243 |
| Physicians who Treat ADHD (US) | 382 |
GLG NewsSM Analyses by Lawrence Ginsberg, MD(?)
1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...
1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...
1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.
1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...
GLG InstituteSM Seminars with Lawrence Ginsberg, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Lawrence Ginsberg, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

